EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Colesevelam has no acute effect on postprandial GLP-1 levels but abolishes gallbladder refilling

Ida M Gether, Emilie Bahne, Henriette H Nerild, Jens F Rehfeld, Bolette Hartmann iD, Jens J Holst, Tina Vilsbøll, David P Sonne, Filip K Knop iD

European Journal of Endocrinology · 2024

DOI: 10.1093/ejendo/lvae033 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Endocrinology, 2024. Verfasst von Ida M Gether und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, DK-2900 Hellerup, Denmark. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: The Danish Medical Association Research Grant, Novo Nordisk Foundation, A. P. Møller Fonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Colesevelam, a bile acid sequestrant approved for the treatment of hypercholesterolaemia, improves glycaemic control in type 2 diabetes. We hypothesised that single-dose colesevelam increases postprandial GLP-1 secretion, thus, reducing postprandial glucose excursions in individuals with type 2 diabetes. Further, we explored the effects of single-dose colesevelam on ultrasonography-assessed postprandial gallbladder motility, paracetamol absorption (proxy for gastric emptying), and circulating factors known to affect gallbladder motility.

Methods

In a randomised, double-blind, placebo-controlled crossover study, 12 individuals with type 2 diabetes (mean ± SD: age 61 ± 8.8 years; body mass index 29.8 ± 3.0 kg/m2) were subjected to 4 mixed meal tests on separate days; 2 with orally administered colesevelam (3.75 g) and 2 with placebo, with intravenous infusion of the GLP-1 receptor antagonist exendin(9-39)NH2 or saline.

Results

Single-dose colesevelam had no effect on postprandial concentrations of glucose (P = .786), C-peptide (P = .440), or GLP-1 (P = .729), and exendin(9-39)NH2 administration revealed no GLP-1-mediated effects of colesevelam. Colesevelam did not affect gallbladder emptying but abolished gallbladder refilling (P = .001), increased postprandial cholecystokinin (CCK) secretion (P = .010), and decreased postprandial serum concentrations of fibroblast growth factor 19 (FGF19) (P = .035) and bile acids (P = .043).

Conclusion

Single-dose colesevelam had no effect on postprandial GLP-1 responses or glucose tolerance but disrupted postprandial gallbladder refilling by increasing CCK secretion and reducing circulating concentrations of FGF19 and bile acids. These findings leave the antidiabetic actions of colesevelam unresolved but provide mechanistic insights into its effect on gallbladder motility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide 1Diabetes Mellitus, Type 2HumansMiddle AgedAgedColesevelam HydrochlorideGallbladderCross-Over StudiesBlood GlucoseGlucoseBile Acids and SaltsPostprandial Period

Stichwörter der Autor:innen

FGF19GLP-1bile acidscolesevelamgallbladder motility

Substanzen

Glucagon-Like Peptide 1Colesevelam HydrochlorideBlood GlucoseGlucoseBile Acids and Salts

Autor:innen und Institutionen

  • Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, DK-2900 Hellerup, Denmark.
  • Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, DK-2100 Copenhagen, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark.
  • Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark.
  • Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark.
  • Steno Diabetes Center Copenhagen, DK-2730 Herlev, Denmark.

ORCID-Profile: Bolette Hartmann, Filip K Knop

Förderung

  • The Danish Medical Association Research Grant
  • Novo Nordisk Foundation
  • A. P. Møller Fonden

Zitieren

APA

Gether, I. M., Bahne, E., Nerild, H. H., Rehfeld, J. F., Hartmann, B., Holst, J. J., Vilsbøll, T., Sonne, D. P., & Knop, F. K. (2024). Colesevelam has no acute effect on postprandial GLP-1 levels but abolishes gallbladder refilling. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvae033

Vancouver

Gether IM, Bahne E, Nerild HH, Rehfeld JF, Hartmann B, Holst JJ, et al. Colesevelam has no acute effect on postprandial GLP-1 levels but abolishes gallbladder refilling. European Journal of Endocrinology. 2024. doi:10.1093/ejendo/lvae033

BibTeX
@article{Gether2024,
  author = {Gether, Ida M and Bahne, Emilie and Nerild, Henriette H and Rehfeld, Jens F and Hartmann, Bolette and Holst, Jens J and Vilsbøll, Tina and Sonne, David P and Knop, Filip K},
  title = {Colesevelam has no acute effect on postprandial GLP-1 levels but abolishes gallbladder refilling},
  journal = {European Journal of Endocrinology},
  year = {2024},
  doi = {10.1093/ejendo/lvae033}
}
Kostenlos starten →